| Cells . | Treatments . | Number of videos . | Number of cell–cell contacts . | Number of repulsions . | Repulsions/cell–cell contacts . |
|---|---|---|---|---|---|
| % | |||||
| HCT116 | No treatment | 22 | 36 | 16 | 44 |
| DMSO (0.3%) | 19 | 32 | 20 | 62 | |
| Blebbistatin | 10 | 25 | 0 | 0 | |
| PCIP | 12 | 35 | 1 | 3 | |
| Control siRNA (10 nM) | 21 | 47 | 20 | 42 | |
| Control siRNA (30 nM) | 20 | 44 | 22 | 50 | |
| Myo1b siRNA (10 nM) | 20 | 48 | 3 | 6 | |
| Fascin siRNA (30 nM) | 21 | 51 | 10 | 20 | |
| HUVECs | DMSO (0.1%) | 12 | 11 | 9 | 81 |
| PCIP | 17 | 23 | 5 | 22 | |
| Control siRNA (10 nM) | 24 | 19 | 16 | 84 | |
| Myo1b siRNA (10 nM) | 20 | 20 | 7 | 35 |
| Cells . | Treatments . | Number of videos . | Number of cell–cell contacts . | Number of repulsions . | Repulsions/cell–cell contacts . |
|---|---|---|---|---|---|
| % | |||||
| HCT116 | No treatment | 22 | 36 | 16 | 44 |
| DMSO (0.3%) | 19 | 32 | 20 | 62 | |
| Blebbistatin | 10 | 25 | 0 | 0 | |
| PCIP | 12 | 35 | 1 | 3 | |
| Control siRNA (10 nM) | 21 | 47 | 20 | 42 | |
| Control siRNA (30 nM) | 20 | 44 | 22 | 50 | |
| Myo1b siRNA (10 nM) | 20 | 48 | 3 | 6 | |
| Fascin siRNA (30 nM) | 21 | 51 | 10 | 20 | |
| HUVECs | DMSO (0.1%) | 12 | 11 | 9 | 81 |
| PCIP | 17 | 23 | 5 | 22 | |
| Control siRNA (10 nM) | 24 | 19 | 16 | 84 | |
| Myo1b siRNA (10 nM) | 20 | 20 | 7 | 35 |